Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on February 4, 2021. The registrant is incorporated in California and reports under Commission File Number 1-37648. The filing addresses a specific corporate event regarding capital markets activity rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves to disclose a corporate event rather than report financial performance metrics.
Material Changes and Events
- Proposed Public Offering: On February 4, 2021, OncoCyte announced the commencement of a proposed underwritten public offering of its common stock.
- Suspension of ATM Program: In connection with the proposed offering, the company suspended sales of common stock under its existing Equity Distribution Agreement with Piper Sandler & Co. (dated March 20, 2020).
- Future Sales Restriction: The company will not make any sales pursuant to the Equity Distribution Agreement unless and until a new prospectus supplement is filed with the SEC. The agreement itself remains in full force and effect.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various factors. Specific risks and contingencies are referenced as being detailed in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The filing explicitly states it does not constitute an offer to sell securities.
Investor Verification Checklist
- Verify the status of the proposed underwritten public offering and whether a new prospectus supplement has been filed.
- Confirm the resumption date for sales under the Equity Distribution Agreement with Piper Sandler & Co.
- Review the most recent Form 10-K or 10-Q for updated financial metrics and risk factors not included in this 8-K.
- Check for any subsequent filings regarding the outcome of the proposed offering.